Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Curr Opin Pulm Med
2013 Jul 01;194:331-9. doi: 10.1097/MCP.0b013e328362075c.
Show Gene links
Show Anatomy links
How and when to use genetic markers for nonsmall cell lung cancer.
Lazarus DR
,
Ost DE
.
???displayArticle.abstract???
PURPOSE OF REVIEW: Many driver mutations that determine the malignant behavior of lung cancer have been identified in recent years. The promise of therapies targeted to the specific molecular pathways altered by such mutations has made genetic testing in nonsmall cell lung cancer (NSCLC) attractive to clinicians. We reviewed recent research on clinically relevant genetic and molecular tests for patients with NSCLC, with an emphasis on the tests linked to actionable mutations that influence therapy and improve outcomes.
RECENT FINDINGS: Mutations in the epidermal growth factor receptor gene (EGFR) and translocations involving the anaplastic lymphoma kinase (ALK) gene have been shown to be common driver mutations in lung adenocarcinoma. The presence or absence of these mutations has been demonstrated to predict response to targeted therapy in many recent studies. Targeted therapies for patients with mutations in the EGFR domain or the echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase translocation have been shown to be effective and are approved for use. Ongoing studies continue to define the extent of their utility and may continue to expand their indications. Sufficient tissue for genetic analysis can be obtained from cytologic samples, including those obtained from endobronchial ultrasound-guided transbronchial needle aspiration.
SUMMARY: Genetic testing for driver mutations is useful in identifying patients with NSCLC who are likely to respond to targeted therapy. These tests are best used in patients with adenocarcinoma who have advanced-stage cancer.
Alberts,
Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd Edition).
2007, Pubmed
Alberts,
Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd Edition).
2007,
Pubmed
Allegrini,
Epidermal growth factor receptor gene analysis with a highly sensitive molecular assay in routine cytologic specimens of lung adenocarcinoma.
2012,
Pubmed
Beasley,
ASCO Provisional Clinical Opinion: Epidermal Growth Factor Receptor Mutation Testing in Practice.
2011,
Pubmed
Billah,
EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens.
2011,
Pubmed
Cohen,
FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.
2003,
Pubmed
Cohen,
FDA drug approval summary: erlotinib (Tarceva) tablets.
2005,
Pubmed
Cohen,
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).
2010,
Pubmed
Costa,
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
2008,
Pubmed
D'Angelo,
Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.
2011,
Pubmed
D'Angelo,
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
2012,
Pubmed
Dogan,
Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.
2012,
Pubmed
Eberhard,
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
2005,
Pubmed
Garcia-Olivé,
Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations.
2010,
Pubmed
Greulich,
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.
2005,
Pubmed
Gridelli,
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.
2012,
Pubmed
Han,
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.
2012,
Pubmed
Haura,
Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
2005,
Pubmed
Inamura,
EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
2008,
Pubmed
,
Echinobase
Jackman,
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.
2009,
Pubmed
Janjigian,
Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.
2011,
Pubmed
Jänne,
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.
2012,
Pubmed
Katayama,
Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: a retrospective case-matching cohort study.
2010,
Pubmed
Kwak,
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
2010,
Pubmed
Lopez Guerra,
Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy.
2013,
Pubmed
Lynch,
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
2004,
Pubmed
Ma,
Personalized targeted therapy in advanced non-small cell lung cancer.
2012,
Pubmed
Maeda,
Late recurrence of non-small cell lung cancer more than 5 years after complete resection: incidence and clinical implications in patient follow-up.
2010,
Pubmed
Maemondo,
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
2010,
Pubmed
Marchetti,
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.
2005,
Pubmed
Marks,
Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.
2008,
Pubmed
Martelli,
EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.
2009,
Pubmed
,
Echinobase
Martini,
Incidence of local recurrence and second primary tumors in resected stage I lung cancer.
1995,
Pubmed
Mitsudomi,
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
2005,
Pubmed
Mitsudomi,
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
2010,
Pubmed
Mok,
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
2009,
Pubmed
Nakajima,
Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration.
2007,
Pubmed
Nakajima,
Multigene mutation analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration.
2011,
Pubmed
Navani,
Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients.
2012,
Pubmed
Paez,
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
2004,
Pubmed
Paik,
Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component.
2012,
Pubmed
Pao,
New approaches to targeted therapy in lung cancer.
2012,
Pubmed
Pao,
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
2004,
Pubmed
Paz-Ares,
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis.
2010,
Pubmed
Perez-Moreno,
Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities.
2012,
Pubmed
Pillai,
The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation.
2012,
Pubmed
Riely,
Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
2006,
Pubmed
Riess,
Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.
2012,
Pubmed
Rosell,
Screening for epidermal growth factor receptor mutations in lung cancer.
2009,
Pubmed
Rosell,
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
2012,
Pubmed
Sakairi,
EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
2010,
Pubmed
,
Echinobase
Santis,
Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.
2011,
Pubmed
Shaw,
Crizotinib and testing for ALK.
2011,
Pubmed
Shaw,
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
2009,
Pubmed
Shaw,
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
2011,
Pubmed
Shepherd,
Erlotinib in previously treated non-small-cell lung cancer.
2005,
Pubmed
Sholl,
EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry.
2010,
Pubmed
Soda,
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
2007,
Pubmed
,
Echinobase
Sordella,
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
2004,
Pubmed
Takahashi,
Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
2010,
Pubmed
,
Echinobase
Torkamani,
Prediction of cancer driver mutations in protein kinases.
2008,
Pubmed
Tsao,
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
2005,
Pubmed
Zhang,
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial.
2012,
Pubmed
Zheng,
Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer.
2005,
Pubmed
Zhou,
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
2011,
Pubmed
